Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal

Bibliography

• Heberden W. Some account of a disorder of the breast. Med Trans R Coll Phys 1772;2:59
   Google Scholar
• Braunwald E, Sobel B. Coronary blood flow and myocardial ischemia. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine. WB Sanders; Philadelphia: 1988. p. 1191-221
   Google Scholar
• Roger VL, Go SA, Lloyd-Jones DM, Heart disease and stroke statistics-2011 update: a report from the American Heart association. Circulation 2011;123:e18-e209; published corrections appear in Circulation. 2011;123:e240 and 2011;124:e426
   PubMed Web of Science ®Google Scholar
• Brorsson B, Bernstein SJ, Brook RH, Quality of life of patients with chronic stable angina before and four years after coronary revascularization compared with normal population. Heart 2002;87:140-5
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, adams RJ, Brown TM, Heart disease and stroke statistics-update: a repot from the American Heart association. Circulation 2010;121:e46-e215
   PubMed Web of Science ®Google Scholar
• Mangoni AA. Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetics, pharmacodynamic and therapeutic considerations. Drugs Aging 2005;22:913-41
   PubMed Web of Science ®Google Scholar
• Thadani U. Medical therapy of stable angina pectoris. Cardiol Clin 1991;9:73-88
   PubMedGoogle Scholar
• Asirvatham S, Sebastian C, Thadani U. Choosing the most appropriate treatment of stable angina: safety considerations. Drug saf 1998;19:23-44
   PubMed Web of Science ®Google Scholar
• Fox K, Garcia MA, Ardissino D, Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of stable Angina Pectoris of the European Society of cardiology. Eur Heart J 2006;27:1341-81
   PubMedGoogle Scholar
• Fraker TD Jr, Fihn SD, Gibbons RJ, 2007 chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients with Chronic Stable Angina; a report of the American college of cardiology/American Heart association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management for the management of patients with chronic stable angina. Circulation 2007;116:2762-72; published correction appear in circulation. 2007; 116; e558
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ong AT, van Herwerden LA, Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease; the final analysis of the arterial revascularization Therapies Study (ARTS) randomized trial. J Am Coll cardiol 2005;46:575-81
   PubMed Web of Science ®Google Scholar
• Boden WE, O’Rourke RA, Teo KK, Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-6
   PubMed Web of Science ®Google Scholar
• Lopaschuk GD, Wambolt RB, Barr RL. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp ther 1993;264(1):135-44
   PubMedGoogle Scholar
• McCormach JG, Barr RL, Thomas PD, Ranolazine stimulates glucose oxidation in normoxic,ischemic, and reperfused ischemic rat hearts. Circulation 1996;93(1):135-42
   PubMedGoogle Scholar
• Lee L, horowitz J, Frenneaux M. Metabolic manipulation in ischemic heart disease, a novel approach to treatment. Eur heart J 2004;25:634-41
   PubMed Web of Science ®Google Scholar
• Ranexa (Ranolazine Extended Releasetablets): FDA Label Document. Available from: http://www.fda.gov/cder/foi/label/2006/021526s0001.pdf
   Google Scholar
• Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, MERLIN-TIMI trial Investigators. Effects of ranolazine on recurrent cardiovascular events in patients with non-st-elevation acute coronary syndromes: the MERLIN-TIMI randomized trial. JAMA 2007;297:1775-83
   PubMed Web of Science ®Google Scholar
• Scirica BM, Morrow DA, Hanoch H, Effect of ranolazine, an antianginal agent with novel electrocardiophysiological properties, on the incidence of arrhythmias in patients with non-st-elevation acute coronary syndrome. MERLIN-TIMI 36 randomized controlled trial. Circulation 2007;116:1647-52
   PubMed Web of Science ®Google Scholar
• Ranexa (Ranolazine Extended Release tablets). Highlights of prescribing information. New FDA approved labeling. 2009. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo
   Google Scholar
• Jerling M. Clinical pharmacokentics of ranolazine. Clin Pharmcokinet 2006;45(5):465-91
   Google Scholar
• Jain D, Lahiri A, Dasgupta P, Rs-43285 [SYNTEX]. A preliminary study of unique anti-anginal agent [abstract]. Clin Sci 1987;73(S17):38B
   Google Scholar
• Jain D, Dasgupta P, Hugh LO, Ranolazine [RS-43285]: a preliminary study of a new anti-anginal agent with selective effect on ischemic myocardium. Eur J Clin Pharmacol 1990;38:111-14
   PubMedGoogle Scholar
• Essamari B, Rousseau MF, D’Hondt A-M, Novel anti-anginal agent increases exercise duration and rate-pressure product in patients receiving diltazem or beta-blocker [abstract]. Circulation 1990;82(Suppl II):III-393
   Google Scholar
• Cocco G, Rousseau MF, Bouvy T, Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with betablocker or diltiazem. J Cardiovasc pharmacol 1992;20:131-8
   PubMed Web of Science ®Google Scholar
• Thadani U, Ezekowitz M, Fenney L, Double –blind efficacy and safety of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine study group. Circulation 1994;90:726-34
   PubMed Web of Science ®Google Scholar
• Thadani U. Current medical management of chronic stable angina. J Cardiovasc Pharacol Ter 2004;9(Supp1):S11-29
   PubMedGoogle Scholar
• Pepine CJ, Wolff AA; Ranolazine Study Group. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J cardiol 1999;84:46-50
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Skettino SL, Parker JO, MARISA Investigators. Anti-ischemic effects and long term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Pepine CJ, Parker JO, CARISA Investigators. Effects of ranolazine with atenolol. Amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA 2004;291:309-16
   PubMed Web of Science ®Google Scholar
• Stone PH, Nikolay AG, Alexy B, ERICA investigators. Antianginal effaciy of ranolazine with added to treatment with amlodipine. The ERICA (Efficacy of Ranolazine in Chronic Angina). J Am Coll Cardiol 2006;48:566-75
   PubMed Web of Science ®Google Scholar
• Rousseau MF, Pouleur H, Cocco G, Wolff A. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. AM J Cardiol 2005;95:311-16
   PubMed Web of Science ®Google Scholar
• Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart j 2006;27:42-8
   PubMed Web of Science ®Google Scholar
• Wenger NK, Chaitman B, vetrovec GW. Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized trials. Am J Cardiol 2007;99:11-18
   Google Scholar
• Mehta PK, Pavel G, Louise EJT, Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging 2011;4:514-22
   PubMed Web of Science ®Google Scholar
• Greene RS, Rangel RM, Edwards KL, Ranolazine for the treatment of refractory angina in a veterans population. Cardiovasc Revasc Med 2012;13:141.el-5
   Google Scholar
• Morrow DA, Scirica FM, Chaitman BR, Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes melitius in the MERLIN-TIMI 36 randomized controlled trial. Circulation 2009;119:2032-9
   PubMed Web of Science ®Google Scholar
• Anzelevitch C, Belardinelli L, Zygmunt AC, Electrophysiological effects of ranolazine, a novel antianginal agent wth antiarrhythmic properties. Circulation 2004;110:904-10
   PubMedGoogle Scholar
• Belardinelli L, Shryock JC, Fraser H. The mechanism of ranolazine action to reduce ischemia induced diastolic dysfunction. Eur Heart J 2006;8:A10-13
   Web of Science ®Google Scholar
• Song Y, Shryock JC, Wu L, Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 2004;44:192-9
   PubMed Web of Science ®Google Scholar
• Burashnikov A, Diego JM, Zygmunt AC, Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007;116:1449-57
   PubMed Web of Science ®Google Scholar